Sep. 16 at 3:31 PM
H.C. Wainwright reiterated
$IMCR Buy/
$100 after hosting
$IMCR's Mgmt Sept. 8, at its well-attended 27th Annual Global Investment Conference.
H.C. Wainwright said:
Management was upbeat on the robust KIMMTRAK revenue growth seen in 1H25, which continues to support the pipeline expansion, including in autoimmune programs.
With a cash position of
$883 million as of June 30, 2025, and a maturing clinical pipeline across multiple therapeutic areas, we believe Immunocore is well positioned for continued growth. We reiterate our Buy
rating and
$100 price target on
$IMCR.
$BMY $MRK $DCTH $IMTX